Vai alla homepage
4.6/5
TrustPilot

Pagina 2 - I migliori medici per il trattamento di Cancro al seno - TOP-63 medici

Confronta i migliori medici di Cancro al seno e i prezzi in Turchia. Trova qui la tua scelta ideale.

Richiedi preventivi da 3 migliori specialisti di in Turchia

Selezioneremo i migliori medici in base alle tue esigenze e al tuo budget.

Medici top

63

Turchia

Recensioni

14000+

Da pazienti reali

Ricevi piani di trattamento personalizzati gratuiti e scegli l'opzione migliore. Nessun impegno · Nessun costo per i nostri servizi

Anadolu Medical Center
Ayhan Erdemir

Ayhan Erdemir

23 anni di esperienza
Clinica certificata da
 Planetree's Gold Certificate
International Accreditation System for Interventional Oncology Services (IASIOS)
Patient choice in Oncology & Hematology Oncology
+7
Località: Turchia, Istanbul

Il medico è un chirurgo generale presso l'Anadolu Medical Center dal 2006, specializzato nel cancro al pancreas. Ha completato la sua formazione medica presso la Facoltà di Medicina dell'Università di Fırat e si è ulteriormente specializzato in chirurgia generale presso il Dr. Lütfi Kırdar KEAH a Istanbul nel 2003. Con esperienza in vari centri sanitari e ospedali, ha anche servito come professore assistente e coordinatore assistente presso la Scuola di Medicina dell'Università di Maltepe. Il medico ha partecipato a corsi avanzati, tra cui il Corso di Chirurgia Citoriduttiva & Hipec e il Programma di Formazione in Chirurgia Robotica da Vinci.<\/p>

Prezzo del pacchetto da$5,000
Memorial Bahçelievler Hospital
Sadi Kerem Okutur

Sadi Kerem Okutur

20 anni di esperienza
Clinica certificata da
International Organization for Standardization
Joint Commission International
Località: Turchia, Istanbul

Il Prof. Sadi Kerem Okutur ha scritto oltre 20 articoli e 10 capitoli di libri sull'oncologia medica, portando una profonda competenza nella cura del cancro al seno.

  • Lavora presso l'Ospedale Memorial Bahçelievler – un centro oncologico di primo piano
  • Membro della European Society for Medical Oncology
  • Vincitore del Premio per la Ricerca in Oncologia della Turkish Medical Oncology Association
  • Professore Associato di oncologia medica
Prezzo del pacchetto da$4,000
Anadolu Medical Center
Mehmet Dogu Canoglu

Mehmet Dogu Canoglu

20 anni di esperienza
Clinica certificata da
 Planetree's Gold Certificate
International Accreditation System for Interventional Oncology Services (IASIOS)
Patient choice in Oncology & Hematology Oncology
+7
Località: Turchia, Istanbul

Dr. Mehmet Doğu Canoğlu is a radiation oncologist. He graduated from Kocaeli University Faculty of Medicine. He completed his residency in radiation oncology at Kocaeli University from 2006 to 2012.

He completed his compulsory service at Diyarbakır Training and Research Hospital. He then worked at Bağcılar Training and Research Hospital and at Medipol Mega University Hospital from 2015 to 2017. Since 2017, he has been a radiation oncologist at Anadolu Medical Center.

Prezzo del pacchetto da$5,000
Anadolu Medical Center
Necdet Uskent

Necdet Uskent

55 anni di esperienza
Clinica certificata da
 Planetree's Gold Certificate
International Accreditation System for Interventional Oncology Services (IASIOS)
Patient choice in Oncology & Hematology Oncology
+7
Località: Turchia, Istanbul

Il medico si è laureato presso la Facoltà di Medicina dell'Università di Ankara e ha completato la formazione in medicina interna presso la Scuola di Medicina di Ankara GATA. Specializzandosi in oncologia medica e ematologia, il medico ha completato una borsa di studio clinica negli Stati Uniti. Pioniere in Turchia, il medico ha fatto parte del team che ha eseguito il primo trapianto di midollo osseo nel paese. Il medico ha servito come docente ospite in istituzioni prestigiose a Londra e in Svizzera. In possesso del Certificato Europeo di Oncologia Medica, il medico è membro fondatore sia della Società Turca di Oncologia Medica che del Gruppo Oncologico Turco. Il focus clinico include tumori al seno, gastrointestinali, polmonari, linfomi e mieloma.<\/p>

Prezzo del pacchetto da$5,000
Istanbul Florence Nightingale Hospital
Murat Atay

Murat Atay

33 anni di esperienza
Clinica certificata da
Joint Commission International
International Organization for Standardization
Località: Turchia, Istanbul

Education:

Teaching course on “Lymphatic mapping and sentinel node”

June 1998, MDA Cancer Center, Houston, Texas, USA

 

General Surgery

Feb. 1993 – Dec. 1996, Şişli Etfal Hospital, Istanbul, Turkey

 

General Surgery

May 1990 – Jan. 1993, Lille University Hospital, Lille, France 

 

M.D.

1983 – 1990, Cerrahpasa School of Medicine, Istanbul, Turkey

 

Experience

 

Attending General Surgeon, Jan. 1998 – present 

F.N. Metropolitan Hospital, Istanbul, Turkey

American Cancer Center, Breast Surgery

 

Attending General Surgeon, 1996 – present 

Medmar Diagnostic Center, Istanbul, Turkey

Diagnosis and monitoring with sophisticated techniques 

 

General Surgeon, 1996 – 1998

Guzelbahce Medical Center and Yeditepe Hospital, Istanbul, Turkey

Specializing in breast and thyroid surgery

 

Visita dal medicoPrezzo su richiesta
Valued Med Hub Hospitals
Saban Sec

Saban Sec

14 anni di esperienza
Clinica certificata da
Turkish Medical Association
International Health Tourism Authorization Certificate
Località: Turchia, Istanbul

Dr. Saban Sec is a medical oncologist with experience at leading hospitals, including Haseki Training and Research Hospital, Prof. Dr. Cemil Taşcıoğlu City Hospital, and Bahçelievler Medikalpark Hospital. He currently represents specialist physicians in the Turkish Medical Oncology Association. He is also a member of the Istanbul Medical Chamber and the Turkish Medical Oncology Association.

Dr. Sec treats breast, lung, gastrointestinal, prostate, urogenital, head and neck cancers, as well as sarcomas and rare tumors. He has published many peer-reviewed articles on cancer prognosis, treatment outcomes, and survival rates. His research includes studies with large patient groups, such as 138 patients with HER2-positive metastatic gastric cancer. Dr. Sec focuses on prognostic factors and treatment responses in different cancers. He is dedicated to improving cancer care.

Prezzo del pacchetto da$1,310
Medipol Mega University Hospital
Ozcan Yildiz

Ozcan Yildiz

76 anni di esperienza
Clinica certificata da
Joint Commission International
Patient choice in Pediatric Oncology & Hematology Oncology
Località: Turchia, Istanbul
Dr. Yildiz has published numerous articles in international peer-reviewed journals, examining topics such as Gastroenteropancreatic neuroendocrine tumors, lipid-lowering treatment, dexamethasone suppression tests, thyroxin therapy, familial Mediterranean fever, and idiopathic thrombocytopenia. These articles have been published in journals such as Medical Oncology, J Endocrinol Invest, Swiss Med Wkly, Int J Cardiol, Eur J Med Res, Ethiop Med J, Gynecol Oncol, Med Hypotheses, Int J Gynecol Cancer, Med Oncol, West Indian Med J, and Cases J.
Prezzo del pacchetto da$1,200
Valued Med Hub Hospitals
Turkan Ozturk Topcu

Turkan Ozturk Topcu

18 anni di esperienza
Clinica certificata da
Turkish Medical Association
International Health Tourism Authorization Certificate
Località: Turchia, Istanbul

Fields of Study and Interests

 Breast Cancer

 Lung Cancer

 Colon Cancer

 Stomach Cancer

 Rectum Cancer

 Ovarian Cancer

 Uterine Cancer

 Liver Cancer

 Esophageal Cancer - Esophagus Cancer

 Kidney Cancer

 Larynx Cancer - Throat Cancer

 Thyroid Cancer

 Head and Neck Cancers

 Gynecological Cancers

 Pancreatic Cancer

 Esophageal Cancer - Esophagus Cancer

 Uterine Cancer

 Brain Cancers - Brain Tumors

 Soft Tissue Cancer - Sarcomas

 Prostate Cancer

 Bladder Cancer

 Bile Duct Cancer

 Testicular Cancer

 Cervical Cancer

 Mouth, Tongue, Lip Cancers

 Gastrointestinal System Cancers

 Bone Tumors

 Trachea and Bronchial Cancers

 Skin Cancers - Skin Cancers

 Skeletal System Tumors

 Gallbladder Cancer

 Mesothelioma

Education

 Cumhuriyet University Faculty of Medicine, 2004

 Istanbul Haydarpaşa Education and Research Hospital Internal Medicine Specialist, 2010

 Karadeniz Technical University Faculty of Medicine Medical Oncology Specialist, 2015

Career

 MD Andeson Cancer Center, USA, 2008

 Sunnybrook Odette Cancer Center Breast Cancer Clinic, Canada, 2017

 Moffit Cancer Center, USA 2022

 Istanbul Haydarpaşa Education and Research Hospital Internal Medicine, 2010

 İdil State Hospital Internal Medicine Clinic, 2011

 Karadeniz Technical University Faculty of Medicine Medical Oncology Clinic, 2015

 Istanbul Göztepe Education and Research Hospital Medical Oncology Clinic, 2018

 Yeniyüzyıl University Gaziosmanpaşa Hospital Medical Oncology Clinic, 2020

 Ataşehir Medicana Hospital, Medical Oncology Clinic, 2022

Prezzo del pacchetto da$1,310
Medical Park Antalya Hospital Complex
20 anni di esperienza
Clinica certificata da
International Health Tourism Authorization Certificate
Località: Turchia, Adalia

Education and Specialization

  • 2006: Kocaeli University Faculty of Medicine
  • 2014: Akdeniz University Faculty of Medicine, Internal Medicine
  • 2018: Akdeniz University Faculty of Medicine, Medical Oncology

Experience

  • 2006 - 2008: Konya Derebucak District Hospital
  • 2009 - 2015: Akdeniz University Hospital
  • 2015: Antalya Kaş State Hospital
  • 2015 - 2016: İnönü University Faculty of Medicine
  • 2016 - 2021: Akdeniz University Hospital
  • 2021 - 2023: Antalya Training and Research Hospital
Prezzo del pacchetto da$7,500
Valued Med Hub Hospitals
Didem Tastekin

Didem Tastekin

21 anni di esperienza
Clinica certificata da
Turkish Medical Association
International Health Tourism Authorization Certificate
Località: Turchia, Istanbul

Medical Oncology

 

Fields of Study and Interests

 Gastrointestinal System (GI) Cancer

 Cancer Vaccines

 Breast Cancers

 Lung Cancer

 Rare Cancers

 

Education

 MD: Necmettin Erbakan University Meram Faculty of Medicine, 1994

 Internal Medicine Specialist Training: Atatürk University Faculty of Medicine, 2004

 Internal Medicine Specialist Training: Kafkas University Faculty of Medicine, 2007

 Medical Oncology Sub-Specialist Training: Selçuk University Faculty of Medicine, 2010

 Medical Oncology Sub-Specialist Training: Istanbul University Oncology Institute, 2013

 

Career

 Assistant Professor: Atatürk University Faculty of Medicine, 2005

 Assist. Prof. Dr.: Kafkas University, 2006-2007

 Minor Assistant Professor: Selçuk University – Medical Oncology, 2007-2010

 Minor Assistant Professor: Istanbul University Oncology Institute – Medical Oncology,

2012-2013

 Specialist Professor: Istanbul University Oncology Institute – Medical Oncology, 2013-2017

 Assoc. Prof. Dr.: Istanbul University Oncology Institute – Medical Oncology, 2017-2023

 Prof. Dr.: Istanbul University Oncology Institute – Medical Oncology, 2023-present

Prezzo del pacchetto da$1,310
Medipol Mega University Hospital
Bunyamin Kaplan

Bunyamin Kaplan

Clinica certificata da
Joint Commission International
Patient choice in Pediatric Oncology & Hematology Oncology
Località: Turchia, Istanbul

Il medico è un oncologo radioterapista altamente qualificato con vasta esperienza nel trattamento di una vasta gamma di tumori utilizzando tecniche avanzate di radioterapia. Ha una comprovata esperienza nel migliorare i risultati dei pazienti attraverso piani di trattamento personalizzati e tecnologia all'avanguardia.<\/p>

Certificato in oncologia radioterapica, il medico ha contribuito a numerosi studi clinici e di ricerca, migliorando la comprensione e l'efficacia dei trattamenti radioterapici. È impegnato nell'apprendimento continuo e ha partecipato a numerose conferenze internazionali per rimanere aggiornato sugli ultimi sviluppi nel campo.<\/p>

Prezzo del pacchetto da$1,200

10 persone hanno richiesto un preventivo lo scorso mese

Lokman Hekim University Ankara Hospital
Yusuf Acikgoz

Yusuf Acikgoz

10 anni di esperienza
Clinica certificata da
International Health Tourism Authorization Certificate
International Organization for Standardization
Località: Turchia, Ankara

Associate Professor Dr. Yusuf AÇIKGÖZ
Specialization: Medical Oncology

Education:

  • 2004-2011: İnönü University Faculty of Medicine
  • 2011-2016: Ankara Numune Training and Research Hospital, Internal Medicine
  • 2017-2022: Health Sciences University, Medical Oncology

Professional Experience:

  • 2016-2017: Bingöl City Hospital, Internal Medicine
  • 2021-2022: Health Sciences University, Medical Oncology
  • 2022-2023: Kastamonu Education and Research Hospital, Medical Oncology
  • 2023-2024: Ohio State University, Medical Oncology
  • 2024-Present: Lokman Hekim University, Medical Oncology, Ankara Hospital

Clinical Trials, Courses, Certifications:

Clinical Trials:

  • 2017-2021: Phase III, CheckMate-649 Study (Assistant Investigator)
  • 2022-Present: Phase III, Fortitude-101 Study (Assistant Investigator)

Courses:

  • 2018: Medicres Basic and Advanced Biostatistics Training Program (ongoing), Istanbul-Vienna
  • 2019: Immuno-Oncology Education Course, March 1-2, 2019, Vienna, Central European Cooperative Oncology Group (CECOG)
  • 2018: Good Clinical Practice Certification, April 7-8, 2018, Ankara, Health Sciences University
  • 2017: Basic Oncology Training Program, November 25-26, 2017, Adana, Clinical Oncology Society
  • 2016: Basic Ultrasonography Course (10 hours theoretical + 10 hours practical), September 24-25, 2016, Ankara, Turkish Emergency Medicine Association

Certifications:

  • Ongoing: ECFMG Certification
  • 2024: CITI Responsible Conduct of Research (The Ohio State University)
  • 2024: CITI IACUC-Laboratory Animal Research (The Ohio State University)
  • 2024: CITI Human Subjects Protection (The Ohio State University)
  • 2024: CITI Good Clinical Practice (The Ohio State University)
  • 2023: Occupational English Test (OET)
  • 2019: International English Language Testing System (IELTS), Total Score: 6.5, May 26, 2019, Ankara, British Council
  • 2017: USMLE Step 2 CK Exam; Score: 244, February 7, 2017
  • 2016: USMLE Step 1 Exam; Score: 215, August 25, 2016

Memberships:

  • American Society of Clinical Oncology (ASCO) - 2022
  • Turkish Society of Medical Oncology - 2020
Visita dal medicoPrezzo su richiesta
Istinye University Liv Hospital Bahcesehir
Tahsin Ozatli

Tahsin Ozatli

2016 anni di esperienza
Clinica certificata da
Best clinic for radiotherapy
Best price for PET/CT
Turkish Medical Association
Località: Turchia, Istanbul

Il medico è un oncologo specializzato nel trattamento dei tumori al seno, ai polmoni e gastrointestinali. Attualmente, il medico pratica presso l'Ospedale Universitario Istinye Liv.

Con una carriera che si estende su molteplici istituzioni prestigiose, il medico ha servito come Specialista in Medicina Interna presso l'Ospedale Statale di Malatya, medico presso la Clinica Oncologica di Ankara e membro del Dipartimento di Oncologia presso l'Ospedale Regionale di Formazione e Ricerca di Erzurum.

Il medico si è laureato presso la Facoltà di Medicina dell'Università di Selcuk e ha ottenuto il titolo di Professore Associato nel 2016.

Visita dal medicoPrezzo su richiesta
VM Medical Park Pendik Hospital
Cemil Bilir

Cemil Bilir

21 anni di esperienza
Clinica certificata da
Joint Commission International
Località: Turchia, Istanbul

Education & Expertise

  • 1998 to 2004 – Istanbul University, Istanbul Faculty of Medicine
  • 2005 to 2009 – Düzce University, Internal Medicine Specialization
  • 2009 to 2010 – Beytüşşebap State Hospital, Compulsory Internal Medicine Service
  • 2010 to 2013 – Bülent Ecevit University, Medical Oncology Specialization
  • 2013 to 2015 – Recep Tayyip Erdoğan University, Medical Oncology Compulsory Service
  • 2015 to Present – Associate Professor, Recep Tayyip Erdoğan University
  • 2015 to 2021 – Lecturer, Medical Oncology, Sakarya University Faculty of Medicine
  • 2020 to Present – Professor, Sakarya University Faculty of Medicine
  • 2020 to Present – Ph.D. Student, Inorganic Chemistry, Sakarya University

Experience

  • 2008 – Cleveland Clinic, Rheumatology & Gastroenterology Rotation
  • 2016 to 2017 – Northeastern University, The Center for Pharmaceutical Biotechnology and Nanomedicine, Boston, U.S.

Professional Memberships

  • TTOD (Turkish Society of Medical Oncology)
  • ASCO (American Society of Clinical Oncology)
  • ESMO (European Society for Medical Oncology)
Prezzo del pacchetto da$6,500
Medipol Bahçelievler Hospital
Nail Paksoy

Nail Paksoy

15 anni di esperienza
Clinica certificata da
Joint Commission International
Località: Turchia, Istanbul


PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

 

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

 

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

  • Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
  • Role: Subinvestigator

2. PFİZER

  • Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
  • Role: Subinvestigator

3. RECITE - AMGEN

  • Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
  • Role: Subinvestigator

4. NAVIGATE - BAYER

  • Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
  • Role: Subinvestigator

5. RUBY - Tesaro (PRA)

  • Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
  • Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

  • Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
  • Role: Subinvestigator

7. ASTRA ZENECA

  • Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
  • Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

  • Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
  • Role: Subinvestigator
  •  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

  • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
  • Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

  • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
  • Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

  • Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
  • Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

  • Authors: Paksoy, Nail, et al.
  • Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

  • Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
  • Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

  • Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
  • Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

  • Authors: HAS SIMSEK, Duygu, et al.
  • Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

  • Authors: TURAL, Deniz, et al.
  • Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

  • Authors: FERHATOGLU, Ferhat, et al.
  • Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

  • Authors: TURAL, Deniz, et al.
  • Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

  • Authors: GÜRBÜZ, Mustafa, et al.
  • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

  • Authors: AY, Seval, et al.
  • Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

  • Authors: CIL, Ibrahim, et al.
  • Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

  • Authors: HIZAL, Mutlu, et al.
  • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

  • Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
  • Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

  • Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
  • Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

  • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
  • Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

  • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
  • Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

  • Authors: DEMIR, Semra, et al.
  • Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

  • Authors: ÖZDEMIR, Seçil Kepil, et al.
  • Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

  • Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
  • Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

  • Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
  • Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

  • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
  • Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

  • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
  • Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

  • Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
  • Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

  • Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
  • Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

  • Authors: Dogan, I., Paksoy, N., & Basaran, M.
  • Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

  • Authors: Dogan, I., Paksoy, N., & Basaran, M.
  • Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

  • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
  • Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

  • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
  • Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

  • Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
  • Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

  • Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
  • Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

  • Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
  • Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

 

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

  • Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

  • Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

  • Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

  • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

  • Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

  • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

  • Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

  • Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

  • Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

  • Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

 

 

Prezzo del pacchetto da$2,500
Medipol Acibadem District Hospital
Gul Alco

Gul Alco

31 anni di esperienza
Clinica certificata da
Joint Commission International
Località: Turchia, Istanbul

Education

  • 1986-1989, Bursa High School, Bursa, Turkey
  • 1989-1995, Istanbul University, Istanbul School of Medicine, Turkey
  • 1999-2003, (Residency) Kadir Has University, School of Medicine, Department of Radiation Oncology, Istanbul, Turkey
  • 2015, (Associate Professor) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
  • 2021, (Professor) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
  • 2024, Istanbul Medipol University, Department of Radiation Oncology, Istanbul, Turkey

Experience

  • 1995-1999, Şişli Florence Nightingale Hospital, Istanbul, Cardiology Department
  • 2003, Gayrettepe Florence Nightingale Hospital, Istanbul, Department of Radiation Oncology
  • 2015, (Associate Professor in Radiation Oncology) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
  • 2021, (Professor in Radiation Oncology) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
  • 2024, Istanbul Medipol University, Department of Radiation Oncology, Istanbul, Turkey
Visita dal medicoPrezzo su richiesta
İstinye University Liv Hospital Topkapı
Irfan Cicin

Irfan Cicin

29 anni di esperienza
Località: Turchia, Istanbul

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

Visita dal medicoPrezzo su richiesta
Büyük Anadolu Hospitals (BAH International)
Muzaffer Al

Muzaffer Al

16 anni di esperienza
Clinica certificata da
Turkish Medical Association
International Health Tourism Authorization Certificate
Turkish Medical Association (Türk Tabıplerı Bırliği)
Località: Turchia, Istanbul

Education

 

Ondokuz Mayıs University Faculty of Medicine (1991)

KTÜ Faculty of Medicine Farabi Hospital (Specialization.1998)

Istanbul University Çapa Faculty of Medicine (Laparoscopic Surgery Training, 2002)

Istanbul University Çapa Faculty of Medicine (Laparoscopic Antireflux Surgery Training, 2006)

Istanbul University Cerrahpaşa Faculty of Medicine (General Surgery Clinic Advance Laparoscopic Surgery, Laparoscopic Bariatric Surgery, Morbid Obesity and Oncological Cancer Surgery Training, 2010i)

 

 

 

 

Visita dal medicoPrezzo su richiesta
Before and after gastric sleeve surgery at Optimed International – visible weight loss result
Onder Surgit

Onder Surgit

31 anni di esperienza
Clinica certificata da
American Accreditation Commission International
Località: Turchia, Tekirdağ

Prof. Dr. Önder SÜRGİT is a General Surgeon in the General Surgery Clinic. Working hours: 09:00–18:00. Core practice areas include laparoscopic surgery, cancer surgery, and bariatric surgery.

Graduated from Hacettepe Faculty of Medicine in 1995. Academic title: Professor. Served as Instructor Surgeon at ITEM (Advanced Medical Technologies Training Center). Held faculty roles at Turgut Özal University and Atılım University, Faculties of Medicine. Also worked at Ankara Medicana Hospital and Optimed Health Group. Foreign language: English.

Visita dal medicoPrezzo su richiesta

Hai visualizzato 20 di 63 medici

Scegliere una clinica all'estero può essere stressante. Da Bookimed, con oltre 800.000 pazienti aiutati, comprendiamo le tue preoccupazioni. Sappiamo come trovare medici affidabili, le migliori opzioni per rapporto qualità-prezzo e soluzioni anche per casi complessi. Siamo qui per guidarti in ogni fase del tuo percorso sanitario.

Yan Matsiivskiy

Capo del team dei coordinatori medici

Oltre 4300+ viaggi assistiti di pazienti

3 anni su Bookimed

278 pazienti da Turkey hanno trovato il loro medico tramite noi questo mese

Come troverai il medico perfetto per te

1

Quiz da 2 minuti

Dicci il tuo obiettivo, budget e tempistiche

2

Abbinamento umano + IA

Il nostro algoritmo trova le corrispondenze, il coordinatore verifica l'idoneità

3

Le tue opzioni pronte

Confronta prezzi, pacchetti, date. Chatta con il tuo coordinatore

Tante opzioni e non sai cosa scegliere?

Il tuo personale Il coordinatore Bookimed ti aiuta a trovare il chirurgo perfetto per le tue esigenze

  • Ti supporta 24/7 in ogni fase
  • Ti aiuta a trovare il medico più adatto e gestisce tutte le comunicazioni con le cliniche
  • Coordina viaggio, alloggio e trasferimenti

Guida il tuo percorso di cura

Coordinatori personali medici qualificati

Peguy Beaugris
Tetyana Hyrych
Zekra Eldeeb
Victoria Olayinka
Iryna Sydorchuk
Tetiana Ihnatiuk

Come scegliere il medico e la clinica giusti: consigli degli esperti

Quando scegli un medico o una clinica, tieni presente questi punti chiave:
Controlla le credenziali
Verifica le certificazioni di enti come ISAPS, JCI o degli ordini medici pertinenti.
Verifica i tassi di successo
Scegli medici con grande esperienza e comprovata competenza nel trattamento specifico.
Leggi le recensioni dei pazienti
Recensioni reali dei pazienti Bookimed per conoscere la loro esperienza.
Assicura una comunicazione efficace
Scegli cliniche che offrono servizio di traduzione per facilitare il trattamento.
Chiedi informazioni sui servizi
Conferma se il prezzo include servizi come alloggio, trasferimenti locali e assistenza post-trattamento per evitare costi nascosti.

Bookimed Insights: Principali specialisti in Cancro al seno in Turchia (2026)

Bookimed ha coordinato 109 richieste di trattamento per Cancro al seno in Turchia, collaborando con 63 specialisti di alto livello. I medici in questa tabella sono selezionati in base alle loro credenziali internazionali, esperienza clinica e risultati dei pazienti. La classifica del 2026 è composta da dati verificati su casi reali e dai programmi attuali delle nostre cliniche partner.
ClassificaMedicoesperienzaBuona scelta perCosa li distingueClinica e posizioneConsulto
#120 anni di esperienzaCasi di carcinoma mammario avanzatoPubblicato ampiamente in oncologia medica con oltre 20 articoli. Riconosciuto con l'Oncology Research Award. Membro attivo della European Society for Medical Oncology.
Turchia
da $130